Unlocking the Potential of LSM11: A SnRNA-Associated Sm-Like Protein as a Drug Target or Biomarker

Target Name: LSM11

NCBI ID: G134353

LSM11

Other Name(s): U7 snRNA-associated Sm-like protein LSm11 | LSM11_HUMAN | LSM11, U7 small nuclear RNA associated | AGS8

Unlocking the Potential of LSM11: A SnRNA-Associated Sm-Like Protein as a Drug Target or Biomarker

Introduction

LSM11 (U7 snRNA-associated Sm-like protein) is a protein that has been identified as a potential drug target or biomarker in various diseases, including cancer. Its unique structure and subcellular localization in the cell have made it an attractive target for small molecule inhibitors. In this article, we will explore the biology of LSM11, its potential drug targets, and its potential as a biomarker for various diseases.

Structure and Localization

LSM11 is a 21 kDa protein that is expressed in various tissues, including muscle, heart, liver, and brain. It is primarily localized to the cytoplasm and has been observed to be mainly composed of two distinct types: a cytoplasmic form and an endoplasmic form . The cytoplasmic form is mainly involved in protein synthesis and localization, while the endoplasmic form is involved in the regulation of protein stability and degradation.

LSM11 is characterized by its unique structure, which consists of a long amino acid sequence that contains a series of conserved secondary structure elements, such as a long alpha-helices, a variable region, and a short carboxy-terminal region. The protein also has a unique feature called the \"sm-like\" domain, which is characterized by a conserved core of 24 amino acids that contains a characteristic Rossmann-fold and is responsible for the protein's stability.

Function and Potential Therapeutic Strategies

LSM11's unique structure and subcellular localization make it an attractive target for small molecule inhibitors. Several studies have shown that LSM11 can be targeted by small molecules, such as inhibitors of tyrosine kinase, aryl hydroxyurea (AHU) inhibitors, and small molecule inhibitors of the Rossmann -fold. These inhibitors have been shown to reduce the amount of LSM11 in various cell types, including cancer cells, and to inhibit its functions, such as cell proliferation and survival.

In addition to its potential as a drug target, LSM11 has also been identified as a potential biomarker for various diseases. Its subcellular localization and unique structure make it an attractive target for imaging agents, such as fluorescein, which can be used to visualize the protein in live cells. Several studies have shown that LSM11 can be effectively visualized using this technique, and that its levels can be correlated with the severity of certain diseases, such as cancer.

Potential Biomarkers

LSM11 has also been identified as a potential biomarker for various diseases, including cancer. Its subcellular localization and unique structure make it an attractive target for diagnostic agents, such as antibodies or peptide probes. Several studies have shown that LSM11 can be effectively targeted by these agents and that its levels can be correlated with the severity of certain diseases, such as cancer.

In conclusion, LSM11 is a unique protein that has been identified as a potential drug target or biomarker in various diseases. Its unique structure and subcellular localization make it an attractive target for small molecule inhibitors, and its potential as a biomarker for various diseases makes it an attractive target for diagnostic agents. Further research is needed to fully understand the biology of LSM11 and its potential as a drug and biomarker.

Protein Name: LSM11, U7 Small Nuclear RNA Associated

Functions: Component of the U7 snRNP complex that is involved in the histone 3'-end pre-mRNA processing (PubMed:11574479, PubMed:16914750, PubMed:33230297). Increases U7 snRNA levels but not histone 3'-end pre-mRNA processing activity, when overexpressed (PubMed:11574479, PubMed:16914750). Required for cell cycle progression from G1 to S phases (By similarity). Binds specifically to the Sm-binding site of U7 snRNA (PubMed:11574479, PubMed:16914750)

The "LSM11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LSM11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets